-+ 0.00%
-+ 0.00%
-+ 0.00%

NUVECTIS ANNOUNCES NXP200 GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR BRAF V600-MUTANT, RECURRENT OR PROGRESSIVE, HIGH-GRADE GLIOMA

Reuters·09/24/2026 12:00:00

Please log in to view news